The Candida auris Alert: Facts and Perspectives
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
The emergence of multidrug-resistant microbes is a never-ending threat and remains a major challenge in modern infectious diseases treatment and control. While most attention and public health efforts have been focused on multidrug-resistant bacteria, an alert has recently been issued about the potential of multiple outbreaks of the uncommon multidrug-resistant Candida auris. The recent global spread of this previously unknown yeast that can be transmitted nosocomially is intriguing and poses interesting questions regarding its epidemiology, pathogenesis, management, and infection control. The first descriptions of Candida auris came from publications from Japan and South Korea in 2009 [1, 2] and involved isolates initially misidentified by conventional biochemical tests. Since that time, invasive infections due to C. auris have been reported from all continents and with increasing frequency (Figure 1) [3], although prevalence in many parts of the world is difficult to estimate. In India, C. auris ranked as the fifth cause of candidemia in intensive care units, accounting for 5.3% of cases [4]. Several outbreaks have been reported, with the largest (>50 cases each) occurring in the United Kingdom (during 2015–2016) and Spain (during 2016–2017) [5, 6]. Genotypic analyses identified distinct clades for each geographical region and the same clonal origin within each clade [3, 7–10], suggesting that C. auris was introduced at different sites and disseminated locally. In the United States, as of 30 September 2017, 166 clinical cases of C. auris have been reported (mostly in New York and New Jersey), and 184 additional cases were identified by screening close contacts of patients [11]. The in vitro susceptibility of C. auris isolates to antifungal drugs is variable. In the absence of clinical breakpoints, different thresholds of susceptibility extrapolated from closely related Candida species have been proposed [3, 4, 7]. Most C. auris isolates are resistant to fluconazole (minimum inhibitory concentration [MIC] required to inhibit growth of 90% of organisms, ≥64 µg/mL) [3, 4, 7, 12]. In vitro resistance to voriconazole is variable (range, 3%–73% of isolates), while other triazoles (posaconazole, itraconazole, and isavuconazole) display better activity [3, 4, 7, 12]. Resistance to amphotericin B was reported in 13%–35% of isolates [3, 4, 7]. While most isolates are susceptible to echinocandins, MICs are higher than those for Candida albicans [3, 4, 7, 12]. Echinocandins are the most effective drugs in animal models [13]. Of concern, about 40% of C. auris isolates are resistant to ≥2 antifungal drug classes, and 4%–10% are resistant to most antifungal agents [3, 12]. Deciphering the mechanisms of resistance in C. auris is work in progress. Several erg11 mutations known to be associated with azole resistance have been identified and were related to distinct geographical clades [3]. Functional genome annotation showed that the C. auris genome encodes multiple transporters of the ABC family and the major facilitator superfamily and is phylogenetically close to that of Candida lusitaniae, another fungus capable of rapid induction of resistance [14]. Sequencing of hotspots in the fks genes of C. auris isolates with elevated echinocandin MICs did not detect any mutation [10, 12]. Because C. auris was unknown before 2009, the question arises whether this species is a newcomer in the world of pathogenic fungi or simply has been not previously recognized. Isolates of C. auris have been commonly misidentified as Candida haemulonii, Candida famata, Rhodotorula glutinis, Saccharomyces cerevisiae, or unspecified Candida species. using conventional biochemical diagnostic procedures. The advent of molecular techniques and recent improvements in mass spectrometry (ie, matrix-assisted laser desorption ionization–time of flight [MALDI-TOF] mass spectrometry) databases allow better recognition of this pathogen. Although C. auris was identified in a few clinical samples 20 years ago [2, 15], several lines of evidence indicate that C. auris has emerged as a novel pathogenic Candida species only during the last decade. Analysis of the international SENTRY collection (15271 Candida isolates, collected between 2004 and 2015) identified only 4 C. auris isolates, all collected since 2009 [3]. None of the US cases were identified prior to 2013 [16]. The fact that C. auris infections are mainly observed among patients with previous antifungal exposure suggests that selective pressure could have played a role in the emergence of this novel pathogen [3, 4]. However, the shift in Candida epidemiology, with an increasing proportion of non-albicans and azole-resistant Candida species, has long preceded the emergence of C. auris [17]. The emergence of C. auris as a human pathogen could have been linked to the acquisition of new virulence traits. However, the identification of distinct geographical clades indicates that this genetic event should ha
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lockhart, S. R., Etienne, K. A., Vallabhaneni, S., Farooqi, J., Chowdhary, A., Govender, N. P., Colombo, A. L., Calvo, B., Cuomo, C. A., Desjardins, C. A., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw691 · Cited by 1,662
Satoh, K., Makimura, K., Hasumi, Y., Nishiyama, Y., Uchida, K., & Yamaguchi, H. (2009) · Microbiology and Immunology · doi:10.1111/j.1348-0421.2008.00083.x · Cited by 1,381
First hospital outbreak of the globally emerging Candida auris in a European hospital
Schelenz, S., Hagen, F., Rhodes, J. L., Abdolrasouli, A., Chowdhary, A., Hall, A., Ryan, L., Shackleton, J., Trimlett, R., Meis, J. F., et al. (2016) · Antimicrobial Resistance & Infection Control · doi:10.1186/s13756-016-0132-5 · Cited by 768
Biofilm-Forming Capability of Highly Virulent, Multidrug-Resistant Candida auris
Sherry, L., Ramage, G., Kean, R., Borman, A., Johnson, E. M., Richardson, M. D., & Rautemaa-Richardson, R. (2017) · Emerging Infectious Diseases · doi:10.3201/eid2302.161320 · Cited by 420
Larkin, E., Hager, C., Chandra, J., Mukherjee, P. K., Retuerto, M., Salem, I., Long, L., Isham, N., Kovanda, L., Borroto-Esoda, K., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02396-16 · Cited by 395
Multidrug-resistant endemic clonal strain of Candida auris in India
Chowdhary, A., Anil Kumar, V., Sharma, C., Prakash, A., Agarwal, K., Babu, R., Dinesh, K. R., Karim, S., Singh, S. K., Hagen, F., et al. (2014) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-013-2027-1 · Cited by 373
Candida auris candidaemia in Indian ICUs: analysis of risk factors
Rudramurthy, S. M., Chakrabarti, A., Paul, R. A., Sood, P., Kaur, H., Capoor, M. R., Kindo, A. J., Marak, R. S. K., Arora, A., Sardana, R., et al. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx034 · Cited by 357
Borman, A. M., Szekely, A., & Johnson, E. M. (2016) · mSphere · doi:10.1128/msphere.00189-16 · Cited by 333
Multidrug-Resistant Candida haemulonii and C. auris , Tel Aviv, Israel
Ben-Ami, R., Berman, J., Novikov, A., Bash, E., Shachor-Meyouhas, Y., Zakin, S., Maor, Y., Tarabia, J., Schechner, V., Adler, A., et al. (2017) · Emerging Infectious Diseases · doi:10.3201/eid2302.161486 · Cited by 297
Draft genome of a commonly misdiagnosed multidrug resistant pathogen Candida auris
Chatterjee, S., Alampalli, S. V., Nageshan, R. K., Chettiar, S. T., Joshi, S., & Tatu, U. S. (2015) · BMC Genomics · doi:10.1186/s12864-015-1863-z · Cited by 247
Cited by
Candida auris: Epidemiology, biology, antifungal resistance, and virulence
Du, H., Bing, J., Hu, T., Ennis, C. L., Nobile, C. J., & Huang, G. (2020) · PLOS Pathogens · doi:10.1371/journal.ppat.1008921 · Cited by 609
On the emergence of Candida auris: climate change, azoles, swamps, and birds
Casadevall, A., Kontoyiannis, D. P., & Robert, V. (2019) · mBio · doi:10.1128/mbio.01397-19 · Cited by 515
“auris is that it recently acquired virulence traits that confer the capacity for virulence (7).”
BackgroundSelf-citationAdeme, M. (2020) · doi:10.2147/idr.s249864 · Cited by 182
Candida auris Forms High-Burden Biofilms in Skin Niche Conditions and on Porcine Skin
Horton, M. V., Johnson, C. J., Kernien, J. F., Patel, T. D., Lam, B. C., Cheong, J. Z. A., Meudt, J. J., Shanmuganayagam, D., Kalan, L. R., & Nett, J. E. (2020) · mSphere · doi:10.1128/msphere.00910-19 · Cited by 159
“auris has emerged as the first fungal pathogen to be designated a global public health threat (2).”
BackgroundEmerging fungal pathogen Candida auris evades neutrophil attack
Johnson, C. J., Davis, J. M., Huttenlocher, A., Kernien, J. F., & Nett, J. E. (2018) · mBio · doi:10.1128/mbio.01403-18 · Cited by 157
Metadata
- Authors
- Lamoth, F., & Kontoyiannis, D. P.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-11-18
- Volume
- 217
- Issue
- 4
- Pages
- 516-520
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2770315396
- Cited by
- 95
- References
- 12
- FWCI
- 7.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Candida auris Alert: Facts and Perspectives. https://app.cochat.ai/papers/10.1093/infdis/jix597
- The paper
- Lamoth, F., & Kontoyiannis, D. P. (2018). The Candida auris Alert: Facts and Perspectives. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jix597
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.